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1. Introduction 
Cardiovascular disease (CVD) is the leading cause of death in the Western World. Evidence 
from post mortem studies demonstrated the presence of atheromatous lesions in coronary 
arteries in children (Stary 2000). It is often thought of as a disease associated with a modern 
sedentary lifestyle and a lipid abundant diet Recently Allam and colleagues (Allam et al. 
2011) have imaged fifty two ancient Egyptian mummies using multi slice computer 
tomography and identified atherosclerotic lesions (arterial wall calcification) in 45% of cases 
with calcification sites located in the aorta, coronary carotid, iliac and femoral arteries as 
well as in peripheral arteries.  
1.1 Cardiovascular epidemiology 
The incidence of CVD is higher than for any cancer or other non-CVD condition. CVD 
caused 29% of global deaths in 2004. It is predicted that by 2030 23 million people will die 
from a CVD. Data from the USA suggests that CVD was responsible for 34% of deaths in 
2006 and over 151,000 Americans who died were <65 years old. The incidence of CVD is 
declining in the Western World even though rates of lifestyle associated risk factors such as 
obesity smoking and type II diabetes mellitus are increasing. The decline is in part due to 
advances in therapeutic and invasive intervention. In creating better outcomes for those 
with acute cardiac conditions, patients develop heart failure which requires longer term 
treatment and monitoring and may in fact be a greater health burden than the acute events 
themselves. 
1.2 Cardiovascular pathophysiology 
The blood vessels (figure 1) of the cardiovascular system are comprised of three layers, the 
tunica intima (endothelium), tunica media (concentric smooth muscle) and tunica adventia 
(longitudinal collagen fibres). The three layers are analogous to the endo-, myo- and 
epicardium of the heart respectively.  
Plaque formation (atherogenesis) is initiated with damage to the endothelium. Cholesterol 
rich low density lipoprotein (LDL) particles enter the intimal layer via the LDL receptor 
protein (Brown and Goldstein 1979), a mosaic cell surface protein that recognizes 
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Fig. 1. A) Low powered haematoxylin and eosin (H&E) histological photomicrograph of a 
normal human artery (x40). B) Medium powered view (x200). AD, adipocytes; L, lumen; *, 
processing artefact; TI, tunica intima; TM, tunica media; TA, tunica adventia. 
apolipoprotein B100 embedded in the LDL particle. It also recognizes apolipoprotein E 
found in chylomicrons and very low density lipoprotein remnants, or intermediate density 
lipoprotein. Macrophage cells accumulate oxidized lipid independently of the LDL receptor 
by endocytosis. This results in formation of juvenile raised fatty streaks within the 
endothelium. The macrophage release their lipid content and cytokines into the intima 
Cytokines stimulate intimal thickening by smooth muscle cell proliferation, which then 
secrete collagen, causing fibrosis (figure 2). The lesion appears raised and yellow.  
 
Fig. 2. Medium powered H&E histological micrograph of an intimal lesion (x200). FC, foam 
cell infiltrate; IC, intimal calcification; L, lumen; TI, tunica intima; TM, tunica media.  
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As the lesion develops, the medial layer of the vessel wall atrophies and the elastic lamina 
becomes disrupted. Collagen forms a fibrous cap over the lesion that appears hard and 
white (known as a fibrolipid plaque). The plaque contains macrophage laden with lipid 
(foam cells) as well as extracellular or ‘free’ lipid within the lesion. The endothelium is now 
in a fragile state. Ulceration of the cap occurs at weak points such as the shoulder region, 
near the endothelial lining. Rupture to the cap can cause turbulent blood flow in the lumen. 
The exposed lipid core causes aggregation of platelets and development of a thrombosis. 
This lesion grows due to further platelet aggregation and is responsible for narrowing of the 
lumen of the artery resulting in localized ischemia. Distal embolization of a piece of such 
thrombus may travel downstream and can completely occlude smaller arteries.  
The symptomatic part of the continuum is known as the acute coronary syndrome (ACS) 
which is due to the rupture/erosion of the plaque. This produces, depending on the plaque 
size, vascular anatomy and presence of collateral vessels, a mismatch between the supply 
and demand for oxygen. A net reduction in supply compared to the demand results in 
ischemia. Tissue hypoxia proceeds resulting in inadequate blood/oxygen perfusion. If blood 
flow is not re-established, cardiac cell necrosis will occur. Post AMI survival results in 
remodelling processes in the myocardium and the development of cardiac failure.  
2. Cardiovascular biomarkers 
Cardiac biomarkers have played an important role in the diagnosis and management of 
patients with CVD since the 1950’s (Gaze and Collinson 2005). The challenge has been the 
identification of a cardiospecific biomarker. A number of biomarkers are available which 
can be used for diagnosis and management of patients with CVD (figure 3). Many are not 
clinically measured due to cost and lack of an evidence base.  
The cardiovascular biomarkers essentially fall into three categories. Those that identify 
patients at risk of atherosclerosis; those associated with plaque destabilisation and those 
which indicate rupture of the plaque and the detection of necrosis and cardiac insufficiency.   
2.1 Plaque formation biomarkers 
2.1.1 Cholesterol and lipid fractions 
Cholesterol and lipoproteins such as oxidized low density lipoprotein (LDL), small dense 
LDL and intermediate density lipoprotein are atherogenic. The laboratory repertoire 
common for the determination of plaque development and progression include the 
measurement of cholesterol, triglycerides, high density lipoprotein (HDL) and calculation of 
LDL (Friedewald et al. 1972). Increasingly apolipoprotein-AI and lipoprotein B100 are 
measured. Direct measurement methods of LDL better reveal individuals at risk of CVD but 
are less often promoted due to the higher cost. A joint consensus statement by the American 
Diabetes Association and American College of Cardiology stated that direct LDL particle 
measurement by nuclear magnetic resonance (NMR) is superior to calculated LDL for 
assessing individual risk of CVD (Brunzell et al. 2008). Other lipid components such as small 
dense LDL and intermediate density lipoprotein which are particularly atherogenic can be 
measured but this is not common practice. Lipoprotein (a) contains a central core of LDL 
which is covalently bonded to a polypeptide chain of apolipoprotein a. This peptide shares 
sequence homology with plasminogen and has been proposed as a mechanism linking 
plaque rupture and the development of thrombosis.  
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Fig. 3. Cardiovascular biomarkers for the assessment of cardiovascular disease. ADH, 
antidiuretic hormone; BML, basement membrane laminin; CRP, c-reactive protein; CD-40, 
cluster of differentiation-40; CK-MB, creatine kinase MB; EGF, epidermal growth factor; 
FFAu, unbound free fatty acid; GDF-15, growth differentiation factor 15; HDL, high densitiy 
lipoprotein; HGF, hepatic growth factor; ICAM-1, intracellular adhesion molecule 1; ICTP, 
type I collagen telopeptide, IL-6, interleukin 6; IL-33, interleukin 33; IMA, ischemia modified 
albumin; LDL, low densitiy lipoprotein; Lp(a), lipoprotein a; MCP, monocytes 
chemoattractant factor; MMP1 to 27, matrix metalloproteinase 1 to 27; PIIINP, procollagen 
III aminopropeptide; PICP, procollagen type I carboxy-terminal peptide; PINP, procollagen 
type I amino-terminal peptide; TIMP1 to 4, tissue inhibitors of matrix metalloproteinase 1 to 
4; TNF-alpha, tumour necrosis factor alpha; VCAM-1, vascular cell adhesion molecule 1; 
VEGF, vascular endothelial growth factor; VLDL, very low density lipoprotein.  
The biggest single cause of plaque initiation and inflammation is modified and oxidized 
LDL; however plaque development, progression and destabilisation are multifactorial. A 
number of assays exist for modified and oxidized LDL however they have not made the 
transition to automated immunoassay analysers. A large number of studies have been 
performed using oxidized LDL, however when this is translated to routine clinical use in the 
general chest pain population, the diagnostic and prognostic efficiency of the marker is 
questionable (Gaze et al. 2006b). 
2.1.2 Homocysteine 
Homocysteine is a sulphur containing amino acid (2-amino-4-sulfanylbutanoic acid, 
C4H9NO2S), closely related to cysteine but with an additional methylene (CH2) group. 
Homocysteine is not derived from dietary sources but rather it is biosynthesized from 
methionine (figure 4). Homocysteine can be recycled back to methionine or converted to 
cysteine catalysed by cystathionine -synthase with pyridoxine (vitamin B6) as a cofactor. 
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Fig. 4. Metabolism of Homocysteine. Homocysteine is biosynthesised by demethylation of 
dietary acquired methionine. Methionine receives adenosine triphosphate (ATP) to give S-
adenosylmethionine (SAM), catalysed by S-adenosylmethionine synthetase. SAM transfers a 
methyl group to X (phospholipid, protein, myelin, catecholamine, polysaccharides, creatine, 
carnitine, DNA, RNA) to form X-CH3. The adenosine is hydrolysed to give homocysteine 
which can be converted back to methionine via tetrahydrofolate (THF) or converted to the 
amino acid cysteine.  
Homocysteine is biosynthesised by demethylation of dietary methionine. Methionine 
receives adenosine triphosphate (ATP) to give S-adenosylmethionine (SAM), catalysed by S-
adenosylmethionine synthetase (EC 2.5.1.6). SAM transfers a methyl group to X-
(phospholipid, protein, myelin, catecholamine, polysaccharides, creatine, carnitine, DNA, 
RNA) to form X-CH3. The adenosine is hydrolysed to give homocysteine which can be 
converted back to methionine via tetrahydrofolate (THF) or converted to cysteine. 
Methionine salvage utilises N5-methyl tetrahydrofolate as the methyl donor and vitamin-
B12 (cobalamin) associated enzyme tetrahydrofolate methyltransferase (EC 2.1.1.13).  
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Deficiencies in folic acid (vitamin B9), pyridoxine (vitamin B6) or cobalamin (Vitamin B12) 
can give rise to a high plasma homocysteine. Homocysteineaemia is associated with 
disruptive damage to the endothelium. In vitro studies have demonstrated that 
homocysteine can induce direct damage to endothelial cells, increase platelet activity, 
increase collagen synthesis, smooth muscle cell proliferation and has pro-coagulant effects.  
The Norwegian Vitamin Trial (NORVIT, clinicalTrials.gov # NCT00266487) was a large 
study of approximately 5000 post AMI subjects who were treated to reduce plasma 
homocysteine concentrations (Bonaa et al. 2006). Patients were randomised to receive one of 
four daily treatment regimens; 0.8 mg folic acid, 0.4 mg vitamin B12 and 40 mg vitamin B6; 
0.8 mg folic acid and 0.4 mg vitamin B12; 40 mg of vitamin B6 or finally a placebo. Patients 
were followed for a median of 40 months for recurrent AMI, stroke and sudden cardiac 
death. Overall, plasma homocysteine concentrations fell by 27% on patients taking folic acid 
and vitamin B12. Risk ratio for the primary end-points was 1.08 (95%CI 0.93-1.25). Treatment 
with vitamin B6 showed similar results with no benefit with regard the primary end point. 
Patients who received the polypharmacy of folic acid, vitamin B12 and vitamin B6 were 
actually at increased risk of a cardiac event. Conversely in the HOPE-2 study, reduction of 
homocysteine by polypharmacy reduced the risk of stroke by 25% (Lonn et al. 2006). 
Homocysteine is elevated in patients with chronic kidney disease (CKD). In the renal HOPE-
2 study (Mann et al. 2008) 307 patients with CKD (eGFR <60 ml/min) at high risk of CVD 
were randomised to folic acid and B vitamin polypharmacy and a further 312 received 
placebo for 5 years. The treated group showed a reduction in mean homocysteine from 15.9 
mol/L to 11.9 mol/L (p=<0.001) but did not reduce in the placebo group. Treatment with 
polypharmacy to reduce plasma homocysteine in CKD patients did not reduce the risk of 
cardiovascular death, recurrent AMI or stroke.  
2.2 Plaque destabilisation biomarkers 
Endothelial injury results in chemotactic recruitment of mononuclear cells within the 
plaque. Interleukin-6 (IL-6) concentrations are increased in patients with established CVD as 
well as those who have an acute coronary syndrome. Kinetically, IL-6 rises and falls rapidly 
but produces an acute phase response. This in turn initiates the production of acute phase 
reactants such as C-reactive protein (CRP) and serum amyloid A protein.  
2.2.1 C-reactive protein 
C-reactive protein (CRP) is a hepatically derived pentraxin of 23KDa released from the liver 
during an acute phase response. Physiologically CRP resembles antibody and binds to 
phosphocholine expressed on the surface of necrotic or dying cells and some bacteria. CRP 
activates the complement system via the C1Q complex. The primary use of CRP is as a 
marker of infection, during which concentrations can be 100-fold higher than the limits of 
normal. CRP rises in response to an increase in plasma IL-6 produced by macrophages. CRP 
has a long plasma half-life and is now understood to be a mediator as well as a marker of 
atherothrombotic disease (Ridker 2003). In CVD patients, values are typically in the range 0-
3 mg/L. Due to the development of sensitive assays, which can accurately report below 5 
mg/L, highly sensitive CRP has been demonstrated to be a strong predictor of future 
cardiovascular events. Sensitive CRP has demonstrated better predictive power for adverse 
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cardiac events than low density lipoprotein (LDL) cholesterol (Ridker 2003). A large number 
of studies have demonstrated that CRP is related to the risk of subsequent cardiac events in 
both patients with and without pre-existing CVD. 
Plasma CRP concentrations of <1, 1 to 3, and >3mg/L correspond to low, moderate, and 
high-risk groups for future cardiovascular events respectively. Individuals with low LDL 
(<130 mg/dL; 3.37 mmol/L) cholesterol but high plasma CRP levels (>3mg/L) represent a 
high-risk group often missed in clinical practice. The addition of CRP to standard 
cholesterol evaluation may provide an improvement to global risk prediction and 
monitoring compliance with preventive intervention. Currently CRP is used as a risk 
predictor for primary prevention intervention. The use of aspirin is associated with a 
reduction in CRP concentrations and subsequent lower CVD event rate. The use of statin 
therapy (3-hydroxy-3-methy;-glutaryl-CoA (HMG-CoA) reductase inhibitors, EC 1.1.1.88) 
for hypercholesterolaemia is also associated with a reduction in serum CRP; suggesting 
statins themselves also exert a direct anti-inflammatory effect.  
Whilst IL-6 may be a more sensitive marker for CVD prediction, it is less readily available in 
clinical chemistry laboratories as a routine assay and is harder to measure due to analyte 
stability and storage conditions. 
2.2.2 Lipoprotein-associated phospholipase A2 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) or platelet-activating factor (PAF) 
acetylhydrolase (EC 3.1.1.47) is a 45kDa intracellular phospholipase which hydrolyzes 
phospholipids in cellular membranes. It catalyses the degradation of PAF to inactive 
products by the hydrolysis of an acetyl group at position sn-2, resulting in the production of 
LYSO-PAF and acetate. It is encoded by the PLA22G gene at loci 6p21.2-p12 and consists of 
441 amino acid residues. Attached to LDL, it is responsible for the hydrolysis of oxidised 
phospholipid in the LDL molecule. Less than 20% of Lp-PLA2 is associated with HDL. Using 
immunohistochemical staining with monoclonal antibodies, it has been demonstrated that 
juvenile plaques show less staining for Lp-PLA2 than rupture-prone or ruptured plaques 
(Kolodgie et al. 2006). In patients with cardiovascular metabolic syndrome, modification of 
Lp-PLA2 through treatment of obesity, hyperlipidaemia and diabetes mellitus (Lp-PLA2 is 
independent of insulin resistance), who would otherwise be at intermediate risk of a future 
cardiac event has shown promise. In a large meta analysis of over 79,000 participants (from 
32 prospective studies) Lp-PLA2 activity and mass demonstrate associations with CVD akin 
to the risk associated with non-HDL cholesterol or systolic blood pressure(Thompson et al. 
2010). Lp-PLA2 is a potential therapeutic target for CVD. 
2.2.3 Myeloperoxidase 
Myeloperoxidase (MPO) is a 144 KDa (144,000 Dalton) peroxidase enzyme (EC 1.11.1.7) 
present in abundance in neutrophil granulocytes and stored in azurophilic granules. The 
gene locus for MPO is 17q23.1. MPO is comprised of two 15 KDa light chains and two 
variable weighted glycosylated heavy chains which bind haem pigment responsible for the 
green colour in puss and mucus. The enzyme catalyses the conversion of chloride 
cosubstrate with hydrogen peroxide to chlorinating oxidants such as hypochlorous acid 
(hypochlorite).  
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MPO is a sensitive predictor of AMI. Patients with unstable plaques have higher 
macrophage and neutrophil counts than patients with stable coronary artery disease. MPO 
degrades the collagen layer of the atheroma making the lesion susceptible to erosion or 
rupture. MPO is a risk factor for long term mortality. A study of 885 patients receiving 
coronary angiography have been studied and followed for 13 years for cardiac mortality. 
MPO independently predicted coronary artery disease. The addition of CRP measurement 
improved risk prediction. Patients with elevated MPO or CRP had a 5-fold risk of cardiac 
mortality compared to a 4 fold risk of cardiac mortality if both markers were elevated 
(Heslop et al. 2010). 
2.3 Plaque rupture 
The classical view of plaque rupture is an increasingly outwardly growing plaque reducing 
the luminal space and thus limiting blood flow. It is now known that 80% of plaques that 
cause an ACS event are actually not flow limiting stenoses. Markers of coagulation are 
raised in the ACS patient and these include prothrombin fragment 1 and 2 and factor VIIa. 
Thrombin/antithrombin complex is often elevated and associated with increased plasma 
cardiac troponin. Inflammatory cells contribute to plaque rupture. Foam cells derived from 
macrophages congregate in the shoulder region of the vulnerable plaque. At this time, the 
foam cells express matrix metalloproteinase enzymes (MMPs). These proteolytic enzymes 
can inactivate zymogens (proMMP) enzymes as well as angiotensin II. A number of MMPs 
are synthesised and released by macrophage. These include interstitial collegnase (MMP-1), 
gelatinase enzymes (MMP-2 and MMP-9) and stromelysin (MMP-3). MMP-1 expression is 
increased by oxidised LDL interferon- gamma (IFN-, IL-1 and tumour necrosis factor 
alpha (TNF-) (Rajavashisth et al. 1999).  
2.4 Chest pain 
Chest pain admissions are resource intensive and account for a large proportion of emergency 
care finances. >11 million patients with chest pain present annually to the emergency 
department in the USA. A final diagnosis of ST segment elevation myocardial infarction 
(STEMI); conferring the highest risk occurs in only 3% of chest pain presentations (Pope et al. 
2000). Similar data are given for the UK. 700,000 annual patient attendances in England and 
Wales are due to chest pain and it is responsible for one quarter of hospital admissions 
(Goodacre et al. 2005). Patients demonstrating STEMI benefit from immediate pharmacological 
thrombolytic therapy or percutaneous coronary intervention with or without stent placement 
in order to establish coronary reperfusion. A large proportion of the remaining 97% of chest 
pain admissions do not have a final diagnosis of ACS (Storrow and Gibler 2000). Biomarkers 
are especially important in identifying those patients without classical electrocardiographic 
(ECG) changes who may have a non ST segment elevation myocardial infarction (NSTEMI).  
2.5 Biomarkers of cardiac ischemia  
The detection of cardiac ischemia prior to myocardial infarction is both a major diagnostic 
and therapeutic challenge. Detection of cardiac ischaemia prior to necrosis is a potential 
therapeutic (pharmacological or invasive) target to limit or prevent cellular necrosis. There 
is currently no gold-standard test for ischemia and currently the only method of detection in 
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routine clinical use is to observe ST segment changes on the ECG. Historically serum lactate 
measurements were used however lactate has an extremely low cardiac specificity. Candidate 
markers including whole blood choline and unbound free fatty acids have been proposed 
however only ischemia modified albumin (IMA) has taken the translational step from a 
basic science investigation into an FDA and CE marked commercial assay.  
2.5.1 Whole blood choline  
Choline is a product of phosphodiesteric cleavage of membrane phospholipids such as 
phosphatidylcholine and sphingomyelin; catalysed by phospholipase D (EC 3.1.4.4). 
Physiologically choline provides cell structural integrity, is the precursor for acetylcholine 
production and a source of methyl groups that participate in the S-adenosylmethionine 
synthesis pathway.  
Whole blood (WBCHO) and plasma choline concentrations increase after stimulation of 
phospholipase D and the activation of coronary plaque cell surface receptors or ischemia. 
Phospholipase D activation in coronary plaques causes stimulation of macrophage by 
oxidised LDL, secretion of MMP and activation of platelets. WHBCO can be measured by 
high performance liquid chromatography coupled to mass spectrometry (HPLC-MS). In a 
study of over 300 patients with suspected ACS, WBCHO measured at admission was a 
significant predictor of cardiac death, cardiac arrest, arrhythmia, heart failure or the need for 
percutaneous coronary intervention at 30 day follow up (Danne et al. 2003). The predictive 
power was enhanced by the addition of either cTnT or cTnI and served not as a marker of 
myocardial cell necrosis but identified patients at high risk with unstable angina. WBCHO is 
therefore a better predictive tool than plasma choline for early risk stratification in patients 
who are cardiac troponin negative on admission. The current detection methodology using 
HPLC-MS is not suitable for urgent clinical use.  
2.5.2 Unbound free fatty acids 
Free fatty acids are produced from the breakdown of triglyceride. The majority of free fatty 
acids (FFA) circulate bound to albumin with a very small percentage appearing as the 
unbound free fatty acid (FFAu) form (Richieri and Kleinfeld 1995). The circulating level of 
FFA is limited to the availability of the albumin binding sites. The mechanism of FFAu 
release is not fully understood however increased catecholamines following cardiac 
ischemia may activate FFA release following lipolysis in adipocytes. FFAu are 14-fold 
higher post PCI, compared to pre procedural concentrations and were higher in those with 
associated ischemic ST segment changes on the ECG (Kleinfeld et al. 1996). An assay using 
recombinant fatty acid binding protein bound to a fluorescent tag (ADIFAB) (Richieri et al. 
1999;Richieri et al. 1992) has been developed and a second generation assay using a 
fluorescent molecular probe (ADIFAB2) and a portable reader makes this a potential early 
marker for the point of care setting. Whilst this marker shows promise in the early phase of 
ischemia induced ACS, further trials are required to evaluate the diagnosis and prognostic 
value of FFAu in the chest pain population.  
2.5.3 Ischemia modified albumin 
A reduction in oxygen supply versus demand causes localized acidosis and the generation 
of free radicals. Copper and zinc ions, normally bound to proteins in the plasma are released 
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from protein binding sites to circulate in the free form (Chevion et al. 1993;Cobbe and Poole-
Wilson 1980;McCord 1985). The N-terminus of albumin binds transition metals such as, 
Co2+, Ni2+ and Cu2+ ions (Sadler et al. 1994). The N-terminus however, is susceptible to 
biochemical alteration (Chan et al. 1995). Following a period of ischemia, a reduction in the 
ability of albumin to bind cobalt is apparent. This is the basis of the albumin cobalt-binding 
test (ACB test) for IMA (figure 5) (Bar-Or et al. 2001). The assay measures the ability of 
albumin to bind a known amount of free cobalt added to the sample. Dithiothreitol (DTT) is 
added which binds the remaining unbound cobalt. The colorimetric change is read 
spectrophotometrically.  
 
Fig. 5. Mechanism of Ischemia Modified Albumin generation: Reduced blood flow results in 
tissue hypoxia1 resulting in a lower pH2. Cu++ is released from plasma proteins3. In the 
presence of ascorbic acid, Cu++ is converted to Cu+4. Cu+ reacts with O2 to form O2–5. 
Superoxide dismutase (SOD) dismutates the O2–, forming H2O26. Normally, H2O2 is 
harmlessly degraded to H2O and O2 by catalase. However, in the presence of metals such as 
copper or iron, H2O2 undergoes the Fenton reaction, forming OH radicals7. Free Cu++ is 
scavenged by HSA, where it binds tightly to the N-terminus. OH are highly reactive 
capable of damaging nucleic acids, lipids and proteins, including albumin. One site of 
damage is the N-terminus, where OH alter the amino acids8. Altered albumin is incapable 
of binding Cu++. Bound copper is released from the albumin9, where it may be taken up 
again by the N-terminus of another albumin in a chain reaction which repeats the process of 
albumin binding and OH formation.  
Kinetically there is a rapid increase in serum IMA. In an angioplasty model, IMA values 
decreased at 6 hours post inflation and returned to baseline by 24 hours (Bar-Or et al. 
2001;Sinha et al. 2006). The magnitude of IMA elevation correlates with the number and 
frequency of balloon inflations (Quiles et al. 2003), the presence of collateral vessels (Garrido 
et al. 2004), the need for revascularisation (Dusek et al. 2006) and is parallel to the 
transmyocardial lactate gradient (Sinha et al. 2006). The half-life of human albumin is 19-20 
days. A truncated modified form would remain in the circulation following production for a 
number of days. The rapid reduction in IMA following the ischemic event suggests the 
modification is transient and reversible. IMA alone has a diagnostic sensitivity of 82% with 
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46% specificity if measured in the first three hours of presentation to the ED (Sinha et al. 
2004). The combination of a positive ECG, cTnT (>0.05 g/L) and IMA however 
demonstrated a 95% sensitivity for diagnosis of ACS. In a study of 538 patients admitted to a 
chest pain evaluation unit, admission measurement of IMA plus cTnT had 100% sensitivity 
for prediction of a final diagnosis of AMI (Collinson et al. 2006). IMA however lacks 
specificity for cardiac tissue and elevations can occur in a number of non-ACS conditions 
including autoimmune diseases, cancers, hepatic cirrhosis, haemorrhagic stroke, renal 
disease, peripheral vascular disease and polytrauma.  
Elevated IMA and cTnT on admission predicts 20% of major adverse cardiac events. IMA 
appear to work best in conjunction with other tests such as cTn or the ECG. One year follow 
up of 208 patients presenting to the emergency department with chest pain demonstrated a 
survival disadvantage in those patients with a serum IMA at admission greater than the 
median concentration of the population group (Consuegra-Sanchez et al. 2008). There were 
17 vs 9 (p=0.08) episodes of angina, 21 vs 10 combined endpoints (p=0.03) and 12 vs 4 12 
month all-cause mortality (p=0.03) in the IMA positive group compared to the IMA negative 
group. 
Although the assay has been cleared for in vitro diagnostic use, two problems remain to be 
resolved with IMA. First is the mechanism by which IMA is generated and the relationship 
to the underlying pathophysiological mechanisms during ischemia. The second is the assay 
format; Very low albumin (Zapico-Muniz et al. 2004;Gaze et al. 2006a) and the presence of 
co-existing lactic acidosis affect assay performance. Finally samples need to be analysed 
within a STAT fashion due to the instability of IMA (Gaze 2009). 
2.6 Biomarkers of cardiomyocyte necrosis 
2.6.1 Cardiac troponins  
Markers of cardiac cell necrosis can be split into those located in the cytoplasm of the cell 
and those that form the structural apparatus which control muscle contraction. The cytosolic 
component contains myoglobin, LD, CK, CKMB as well as fatty acid binding protein 
(FABP). The structural compartment consists of the troponin proteins troponin T and 
troponin I (figure 6). Troponins have tissue specific isoforms. Cardiac troponin T (cTnT) and 
cardiac troponin I (cTnI) and are expressed uniquely in myocardial cells, whilst 
predominantly structural both cardiac troponins (cTn) have a small unbound cytosolic 
fraction (between 6% and 8% for cTnT and 2.8%-8.3% for cTnI).  
The measurement of cardiac troponin is now considered the “Gold Standard” test for 
myocardial necrosis and the globally accepted ESC/ACCF/AHA/WHF universal definition 
of AMI has been widely adopted (Thygesen et al. 2007). The success of the measurement of 
troponin is due to the analytical and clinical sensitivity and specificity of the assays and the 
large evidence base for outcome prediction. 
The sensitivity of any biochemical test is dependant on its ability to discriminate between 
the normal and abnormal state. A test that is elevated in all patients with a condition and is 
normal in all controls will have a sensitivity of 100%. Sensitivity is influenced by the 
background level of signal in the normal state and is referred to as noise. This in turn is 
compared to the change of signal in the abnormal state, known as the signal to noise ratio. It 
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Fig. 6. (A) Anatomy of the sarcomere. (B) Structure of the troponin-tropomyosin complex. 
Composed of three proteins, troponin T (TnT, 39.7 kDa), which binds tropomyosin, troponin 
C the Ca2+ binding element (TnC, 18 kDa) and troponin I, the Mg2+ dependent ATPase 
inhibitor (TnI, 22.5 kDa), shown in the resting state. (C) During muscle contraction, Ca2+ is 
released from the t-tubules, and bind TnC, leading to a conformational change in the 
complex  
was presumed that the circulating concentration of cTn in apparently healthy people was 
absolute zero, due to the intracellular location of the proteins. With the advent of more 
sensitive immunoassay methods the current commercial cTn assays demonstrate a 
background level in the circulation that appears to be determined by the detection limit of 
the assay. Although there may be a background level of cTn in the circulation, this is 
undetectable in the majority of cases by the assays currently commercially available. 
Elevation occurs only where there is myocardial damage. The combination of low 
background noise with cardiospecificity means that although in absolute terms the amount 
of cTn released is less than the amount of CKMB, the ability to detect it is much greater, and 
the signal to noise ratio is much higher. Using cTn specific assay, it has been demonstrated 
that elevations of the cardiac isoform do not occur where there is pure skeletal muscle 
trauma. In a study of 696 apparently healthy individuals aged 18-84 years, of which 45% 
were male, two commercial cTnI assays have demonstrated a gender difference, with a 
higher upper limit of normal in males. The other five cTnI assays and the cTnT assay tested 
did not demonstrate a gender difference. In the same population, CKMB mass was 
significantly higher in males compared to females (Apple et al. 2003).  
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Clinical studies of cTn have concentrated on the diagnostic and prognostic utility of the 
assays. Initial studies showed that cTnT could be detected in a significant proportion of 
patients who were classed as having unstable angina using the conventional World Health 
Organisation (WHO) criteria for myocardial infarction. In these studies, both short term and 
long term follow up showed that an elevated troponin was associated with an increased risk 
of cardiac event (Hamm et al. 1992).  
Determination of cTn is by immunoassay. For both cTnT and cTnI, several generations of 
assay have existed and have been comprehensively reviewed (Collinson et al. 2001a). The 
measurement technology utilising electrochemiliuminesence for cTnT is supplied by one 
manufacturer (Roche Diagnostics) due to patent restrictions on the antibodies selected for 
the assay. Measurement of cTnI however is available on a range of immunoassay platforms 
from different manufacturers. Due to a lack of assay standardisation both for a common 
calibrator and for antibody selection, comparison between cTnI methods is often 
problematic. Despite this, a similar series of studies for the different cTnI methods has 
shown that cTnI elevation predicts adverse cardiac events in patients with unstable angina 
(Antman et al. 1996;Galvani et al. 1997;Collinson et al. 2001b). The use of cTnT and cTnI 
determinations results in approximately reclassification of 33% of unstable angina patients 
into patients who have suffered an AMI. 
A number of manufactures have reformulated their assays or introduced high sensitive cTn 
with the aim of meeting the analytical requirements suggested in the universal definition of 
AMI. The introduction of such assays provides challenges both in terms of the analytical 
performance and validation/interpretation procedures for the laboratory and the relevance 
in the clinical setting. Many of these assays can now demonstrate a normal distribution of 
detectable cTn concentrations within a reference population (Collinson et al. 2009a) (Apple et 
al. 2010;Mingels et al. 2009) allowing more robust calculation of the 99th percentile 
concentration to define normality. These assays also allow the calculation of the biological 
variability of cardiac troponin (Wu et al. 2009).  
The introduction of high sensitivity cTn assays will affect the clinical interpretation results. 
There will be a greater number of positives outside the remit of ACS, but within the ACS 
population, it may be possible to diagnose AMI earlier. Using the Centaur TnI-Ultra a 99th 
percentile of 0.039 g/L (39ng/L) has been obtained from a population of 309 (41% male) 
apparently healthy individuals highly screened for cardiac risk factors. These included no 
history of vascular disease, diabetes mellitus, hypertension, or heavy alcohol intake, no 
cardiac medication, no renal failure (eGFR >60 mL/min/1.73 m2), no significant cardiac 
disease on echocardiography, with a left ventricular ejection fraction of >50% (Collinson et 
al. 2009b). Within the reference population, cTnI was completely undetectable in 25 subjects 
and considered negative in 53%. There was no correlation between cTnI and age and there 
were no significant differences between gender (Collinson et al. 2009b). Using the same 
population, the researchers have defined the 99th percentile of the hs-cTnT assay (Roche 
Diagnostics) to be 15.5 ng/L and 42 ng/L for the Beckman Coulter enhanced AccuTnI assay. 
Of note are the differences between the numbers of detectable cTn by assay within the same 
reference population. Detectable concentrations were achieve in 58% of samples when 
measured using the hs-cTnT assay, 68% using the TnI-Ultra and 98% using the Access 
AccuTnI.  
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The prognostic value of the AccuTnI assay has been demonstrated in the Orbofiban in 
Patients with Unstable Coronary Syndromes (OPUS)-Thrombolysis in Myocardial Infarction 
(TIMI) 16 (OPUS-TIMI 16) clinical trial (Morrow et al. 2003). A cut point of >0.04 g/L (>40 
ng/L) was an independent predictor of the 30-day risk of death (odds ratio, OR), 4.1; (95%CI 
1.2-13.8), death and AMI (OR, 3.4; 95%CI, 1.8-6.7), and death, MI, or ; 95% confidence 
interval, 95%CI) need for urgent revascularisation (OR, 2.3; 95%CI, 1.5-3.6) and was also 
associated with risk of death or development of a further AMI at 10 months.  
Using the TnI-Ultra compared to the previous Centaur assay, Melanson and colleagues 
(Melanson et al. 2007) compared the rates of positivity obtained between the two assays over 
a 24 hour period in 103 patients who presented initially with a negative cTnI but converted 
to cTnI positive. TnI-Ultra was positive before cTnI in 66(64.1%) of cases demonstrating 
superior sensitivity. Furthermore, a single admission cTn measurement using hs-cTnI may 
be a useful rule-out test irrespective of the length of chest pain (Keller et al. 2009). Reichlin 
and colleagues also demonstrated excellent diagnostic performance of sensitive cTn assays 
at presentation (Reichlin et al. 2009).  
It has been postulated that sensitive cTn, given the detection in asymptomatic healthy 
people without a history of cardiovascular disease; may be of value in identifying subjects at 
long term risk of ACS, i.e. cTn may have a role in primary prevention (Apple 2011). In a 
large community cohort of adults > 65 years; baseline and delta change in serial hs-cTnT 
measurements are associated with heart failure and cardiac death (deFilippi et al. 2010). 
Further, the use of N-terminal pro-b-type natriuretic peptide (NTproBNP) nor high sensitive 
CRP added to the risk assessment. In a second cohort of >3500 subjects aged 30-65 years 
recruited to the Dallas Heart Study, demonstrable hs-cTnT occurred in 25% of subjects; with 
higher rates in men compared to women (37% vs 13%) respectively. (de Lemos et al. 2010). 
There was separation in rates of positivity in those aged <40 and >60 years of age. Elevated 
hs-cTnT was associated with structural heart disease (left ventricular hypertrophy and left 
ventricular systolic dysfunction) and chronic kidney disease. The overall cardiovascular 
burden as measured by hs-cTnT in primary care may indicate end organ cardiac damage. 
2.7 Heart failure 
Survival rates following AMI are increasing, primarily due to a combination of early 
diagnosis and a rapid therapeutic or invasive intervention to open occlusions and to salvage 
myocardial tissue. Patients with some degree of damaged myocardium however further 
develop cardiac failure. Cardiac failure is a pathophysiological state in which an 
abnormality of cardiac function is responsible for the failure of the heart to pump blood at a 
rate commensurate with the requirements of the metabolising tissues. Cardiac failure affects 
0.4-2% of the population and the age adjusted mortality due to cardiac failure is increasing 
(Remme and Swedberg 2001). There is a 50% survival rate four years after diagnosis (Cowie 
and Zaphiriou 2002). Currently, the clinical diagnostic methodologies available are 
inadequate due to poor sensitivity and specificity. There is heavy reliance on the 
identification of heart failure from symptoms, ECG changes and/or chest x-ray diagnosis. 
The ‘gold standard’ for diagnosis of cardiac failure is currently cardiac imaging technology 
including echocardiography or magnetic resonance imaging; however these are often 
expensive and not always routinely available. A blood borne marker of cardiac dysfunction 
is therefore highly desirable. 
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B type natriuretic peptide (BNP) is a hormone secreted predominantly by ventricular wall 
myocytes in response to increased ventricular stretch. It is not stored following production, 
but is under constant renewal by transcription and translation of mRNA. A prohormone 
proBNP is produced within the myocyte. This prohormone is cleaved by the enzyme corin 
to give the active portion of the molecule, B type natriuretic peptide (BNP) and the N 
terminal portion of the hormone, NTproBNP. Both are available as routine biomarker assay 
tests on a range of immunoassay platforms. The half-life of the active BNP is short (20 
minutes) compared to that of the NTproBNP (120 minutes).  
Measurements of NTproBNP and BNP are used in the diagnosis of suspected acute or 
chronic cardiac failure. It has been demonstrated that the measurement of BNP/NTproBNP 
allows exclusion with a high certainty of left ventricular systolic dysfunction (LVSD) in 
patients presenting to primary care with symptoms suggestive of heart failure, mainly 
shortness of breath (McDonagh et al. 2008;Cowie et al. 1997;Zaphiriou et al. 2005). It has been 
suggested, therefore, that BNP/NTproBNP measurement should be used as the “gold 
standard” test for the detection of ventricular dysfunction. In a prospective randomised trial 
of diagnosis based on BNP with conventional clinical diagnosis in 452 patients, the 
diagnostic pathway including BNP produced reduction in hospital stay; stay in intensive 
care and lower cost but with equivalent mortality (Mueller et al. 2004).  
The role of BNP/NTproBNP in patients presenting with ACS however remains more 
uncertain. Studies have shown that measurement of NTproBNP/BNP on admission in both 
selected and unselected suspected ACS patients can be used to predict outcome. A study of 
2525 patients enrolled in a clinical trial (OPUS-TIMI 16) with a mixed population of ST 
segment elevation MI (STEMI), non ST segment elevation MI (NSTEMI) and unstable angina 
pectoris (UAP) showed that quartiles of BNP concentrations were predictive of survival. 
There was a 9% mortality rate in the highest quartile compared with less than 1% in the 
lowest quartile at 10 months follow up. The population was dichotomised into those with 
BNP above or below the cut point of 80pg/L. An elevated BNP >80pg/mL showed a 
significantly greater risk of death, heart failure or MI both at 30 days and at 10 months (de 
Lemos et al. 2001). In a study of 666 patients admitted with AMI, BNP and NTproBNP were 
measured 24-96 hours from symptom onset. Subsequent death or heart failure was 
predicted by BNP/NTproBNP levels even when ejection fraction exceeded 40% (Richards et 
al. 2003). BNP/NTproBNP measurements have been combined with other biomarkers 
including CRP and cTn (Sabatine et al. 2002) or cTn alone (Jernberg et al. 2002) 
Measurements of BNP/NTproBNP provide additive information under these circumstances 
with the worst prognosis seen when the greatest number of biomarkers are elevated.  
3. Conclusion 
There are a number of cardiovascular biomarkers that aid the clinician in the identification 
of the risk of developing cardiovascular disease. Many are specialised tests and are not 
offered in the routine clinical chemistry laboratory. A large evidence base exists for those 
that are commonly measured as markers of the acute coronary syndrome. Biomarkers 
should be used in an algorithm along with the clinical signs and the results of other 
diagnostic modalities such as the ECG, stress test or echocardiography.  
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Any novel cardiac biomarker should prove clinically useful and cost effective with the 
ultimate aim of altering patient management and reduce mortality. The cardiac troponins 
are the most successful of the candidate markers and have influenced an alteration to the 
definition of acute myocardial infarction. The B type natriuretic peptide has a large evidence 
base for the diagnosis and more importantly the monitoring of heart failure. A reliable 
marker of cardiac ischemia remains to be demonstrated and is the focus of current research 
studies.  
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